erlotinib has been researched along with delgocitinib in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (delgocitinib) | Trials (delgocitinib) | Recent Studies (post-2010) (delgocitinib) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 31 | 10 | 31 |
| Protein | Taxonomy | erlotinib (IC50) | delgocitinib (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0745 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.8 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0203 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.0533 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for erlotinib and delgocitinib
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |